Somewhat Favorable News Coverage Somewhat Unlikely to Impact Acceleron Pharma (NASDAQ:XLRN) Stock Price
News stories about Acceleron Pharma (NASDAQ:XLRN) have been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Acceleron Pharma earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.343513399021 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have impacted Accern’s rankings:
- Brokerages Expect Acceleron Pharma Inc. (NASDAQ:XLRN) Will Post Quarterly Sales of $3.45 Million (americanbankingnews.com)
- Luspatercept: Opportunity for Celgene’s Long-Term Growth? (finance.yahoo.com)
- Ravindra Kumar Sells 13,065 Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) Stock (americanbankingnews.com)
- Acceleron Pharma Inc. (XLRN) Price Target Raised to $44.00 at Citigroup Inc. (americanbankingnews.com)
- Credit Suisse Group Analysts Give Acceleron Pharma Inc. (XLRN) a $35.00 Price Target (americanbankingnews.com)
XLRN has been the topic of several recent analyst reports. Oppenheimer Holdings, Inc. set a $40.00 target price on Acceleron Pharma and gave the stock a “buy” rating in a research report on Thursday, June 1st. Cann reiterated a “buy” rating and set a $40.00 target price on shares of Acceleron Pharma in a research report on Thursday, June 1st. FBR & Co reiterated a “buy” rating on shares of Acceleron Pharma in a research report on Thursday, May 18th. Instinet reiterated a “buy” rating and set a $58.00 target price on shares of Acceleron Pharma in a research report on Wednesday, June 14th. Finally, BidaskClub upgraded Acceleron Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Acceleron Pharma currently has a consensus rating of “Buy” and an average target price of $41.53.
Shares of Acceleron Pharma (NASDAQ:XLRN) opened at 34.10 on Friday. The company has a 50 day moving average price of $32.33 and a 200-day moving average price of $28.88. Acceleron Pharma has a 12-month low of $23.07 and a 12-month high of $41.69. The firm’s market cap is $1.32 billion.
Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.65) by $0.12. The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.69 million. Acceleron Pharma had a negative net margin of 724.22% and a negative return on equity of 44.67%. The business’s quarterly revenue was down 3.1% on a year-over-year basis. During the same period last year, the firm posted ($0.59) EPS. Analysts expect that Acceleron Pharma will post ($2.73) EPS for the current year.
In related news, SVP Ravindra Kumar sold 937 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $32.00, for a total transaction of $29,984.00. Following the sale, the senior vice president now owns 96,264 shares of the company’s stock, valued at $3,080,448. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Kevin F. Mclaughlin sold 34,400 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $32.00, for a total value of $1,100,800.00. Following the sale, the chief financial officer now directly owns 80,950 shares in the company, valued at approximately $2,590,400. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 64,402 shares of company stock worth $2,105,416. Corporate insiders own 3.90% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first posted by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/08/12/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-acceleron-pharma-nasdaqxlrn-stock-price.html.
About Acceleron Pharma
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.